World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0026469213
Reproduction Date:

Title: Talampanel  
Author: World Heritage Encyclopedia
Language: English
Subject: RO4491533, MMPIP, LY-307,452, LY-344,545, PCCG-4
Publisher: World Heritage Encyclopedia


Systematic (IUPAC) name
(8R)-7-Acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h] [2,3]benzodiazepine
Clinical data
Pregnancy cat.
  • N/A
Legal status
  • investigational
CAS number  N
ATC code None
ChemSpider  N
Chemical data
Formula C19H19N3O3 
Mol. mass 337.372 g/mol

Talampanel (GYKI 537773; LY300164) is a drug which has been investigated for the treatment of epilepsy,[1][2] malignant gliomas[3] and amyotrophic lateral sclerosis (ALS).[4]

As of May 2010, results from the trial for ALS have been found negative.[5] Talampanel is not currently under development.

It is a noncompetitive antagonist of the AMPA receptor, a type of glutamate receptor in the central nervous system.[6]


  1. ^ Luszczki, J. J. (2009). "Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions". Pharmacological reports : PR 61 (2): 197–216.  
  2. ^ Bialer, M.; Johannessen, S. I.; Kupferberg, H. J.; Levy, R. H.; Perucca, E.; Tomson, T. R. (2007). "Progress report on new antiepileptic drugs: A summary of the Eighth Eilat Conference (EILAT VIII)". Epilepsy Research 73 (1): 1–52.  
  3. ^ Iwamoto, F. M.; Kreisl, T. N.; Kim, L.; Duic, J. P.; Butman, J. A.; Albert, P. S.; Fine, H. A. (2010). "Phase II Trial of Talampanel, a Glutamate Receptor Inhibitor, for Adults with Recurrent Malignant Gliomas". Cancer 116 (7): 1776–1782.  
  4. ^ Pascuzzi, R. M.; Shefner, J.; Chappell, A. S.; Bjerke, J. S.; Tamura, R.; Chaudhry, V.; Clawson, L.; Haas, L.; Rothstein, J. D. (2009). "A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis". Amyotrophic Lateral Sclerosis 11 (3): 266–271.  
  5. ^ Talampanel Trial, Talampanel Trial on
  6. ^ Aujla, P. K.; Fetell, M. R.; Jensen, F. E. (2009). "Talampanel suppresses the acute and chronic effects of seizures in a rodent neonatal seizure model". Epilepsia 50 (4): 694–701.  

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.